Dedicated view
After Conservative / Palliative Care
This view includes only public records whose official title or study scope explicitly states advanced, metastatic, recurrent, refractory, later-line, supportive care, or palliative. TrialBeacon makes no screening judgment, matching, or recommendation — it simply gathers the literally relevant official entries together and provides direct links to the originals. Whether a record is still open, or relevant to any individual situation, should be determined from the official original and your physician’s judgment.
Showing the verified snapshot of official records indexed on 2026-08-16. Every link opens the live original page.
Includes only public records whose official title explicitly mentions advanced / recurrent / later-line / supportive care. No recommendations, no matching — only links to the originals. Defer to the official page and your physician’s judgment.
Please read this first. A record appearing here does not mean it is open, available or appropriate for any individual. Inclusion is based only on wording in the official record — never on any judgement by this site. Discuss anything you find with your treating doctor.
Trial records retrieved live from the ClinicalTrials.gov public API.
Select the public official records you want to take to your appointment, then generate a list. Nothing is ranked or recommended — the list only reproduces titles and links.
Not signed in — up to 5 records per list. Sign in for higher free limits, or see Pro for more exports.
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel
Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Roll-over Study to Allow Continued Access to Ribociclib
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
A Real-World Observational Study of Intratumoral H101 Oncolytic Adenovirus Combined With Immune Checkpoint Inhibitors for Advanced Metastatic Breast Cancer
A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
Assessing the Time Demands of Cancer
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
HER2-positive Breast Cancer Without Intravenous Neoadjuvant Therapy
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
PRE-ISPY Phase I/II Oncology Platform Program
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
ChiCTR — Chinese Clinical Trial Registry, public search
CTIS public register — search clinical trials authorised in the EU/EEA
ESMO Clinical Practice Guidelines — supportive and palliative care section
FDA — expanded access (compassionate use) information for patients
NCCN Guidelines — palliative care category listing
NCCN Guidelines for Patients — plain-language versions
药物临床试验登记与信息公示平台 — national registry of drug trials conducted in China
Whether a record is still open, current, or appropriate for any individual can only be confirmed by the official source and your treating doctor.
Ways to open the conversation with your doctor (reference only, not advice)
A template only — it teaches how to ask, and gives no answers. Adapt these to your own situation.
- Are these public records still searchable or open to enrolment?
- From the literal wording of the public titles, is there any point relevant to the current situation?
- If there is something relevant, what should I ask you about next?
- For symptoms, pain or supportive care, is there a public guideline worth prioritising as a reference?
These are only examples to help you start a conversation. They are not medical advice. All decisions should be made together with your treating doctor.